|
|
Blood, 1 May 2005, Vol. 105, No. 9, pp. 3615-3622.
Prepublished online as a Blood First Edition Paper on January 18, 2005; DOI 10.1182/blood-2004-07-2585.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Ligands for natural killer cell–activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias
Pegah Nowbakht,
Mihai-Constantin S. Ionescu,
Andreas Rohner,
Christian P. Kalberer,
Emmanuel Rossy,
Lucia Mori,
David Cosman,
Gennaro De Libero, and
Aleksandra Wodnar-Filipowicz
From the Department of Research, Experimental Hematology and Experimental Immunology, University Hospital Basel, Switzerland; and Amgen Washington Inc, Seattle.
Natural killer (NK) cell–mediated cytolytic activity against tumors requires the engagement of activating NK receptors by the tumor-associated ligands. Here, we have studied the role of NKG2D and natural cytotoxicity receptors (NCRs) in the recognition of human leukemia. To detect as-yet-unknown cell-surface molecules recognized by NCRs, we developed soluble forms of NKp30, NKp44, and NKp46 as staining reagents binding the putative cognate ligands. Analysis of UL16-binding protein-1 (ULBP1), ULBP2, and ULBP3 ligands for NKG2D and of potential ligands for NKp30, NKp44, and NKp46 in healthy hematopoietic cells demonstrated the ligand-negative phenotype of bone marrow–derived CD34+ progenitor cells and the acquisition of cell-surface ligands during the course of myeloid differentiation. In acute myeloid leukemia (AML), leukemic blasts from approximately 80% of patients expressed very low levels of ULBPs and NCR-specific ligands. Treatment with differentiation-promoting myeloid growth factors, together with interferon- , upregulated cell-surface levels of ULBP1 and putative NCR ligands on AML blasts, conferring an increased sensitivity to NK cell–mediated lysis. We conclude that the ligand-negative/low phenotype in AML is a consequence of cell maturation arrest on malignant transformation and that defective expression of ligands for the activating NKG2D and NCR receptors may compromise leukemia recognition by NK cells.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Diermayr, H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al.
NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities
Blood,
February 1, 2008;
111(3):
1428 - 1436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cerboni, A. Zingoni, M. Cippitelli, M. Piccoli, L. Frati, and A. Santoni
Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis
Blood,
July 15, 2007;
110(2):
606 - 615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Saikali, J. P. Antel, J. Newcombe, Z. Chen, M. Freedman, M. Blain, R. Cayrol, A. Prat, J. A. Hall, and N. Arbour
NKG2D-Mediated Cytotoxicity toward Oligodendrocytes Suggests a Mechanism for Tissue Injury in Multiple Sclerosis
J. Neurosci.,
January 31, 2007;
27(5):
1220 - 1228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. North, I. Bakhsh, C. Marden, H. Pittman, E. Addison, C. Navarrete, R. Anderson, and M. W. Lowdell
Tumor-Primed Human Natural Killer Cells Lyse NK-Resistant Tumor Targets: Evidence of a Two-Stage Process in Resting NK Cell Activation
J. Immunol.,
January 1, 2007;
178(1):
85 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Fauriat, S. Just-Landi, F. Mallet, C. Arnoulet, D. Sainty, D. Olive, and R. T. Costello
Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction
Blood,
January 1, 2007;
109(1):
323 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. von Strandmann, H. P. Hansen, K. S. Reiners, R. Schnell, P. Borchmann, S. Merkert, V. R. Simhadri, A. Draube, M. Reiser, I. Purr, et al.
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
Blood,
March 1, 2006;
107(5):
1955 - 1962.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
